In brief
- The bipartisan PATH Caucus of the US Congress has published a report summarizing responses to the public consultation launched in 2024.
- It recommends federal guidelines, multiple credentialing pathways for therapists, a national adverse-event monitoring system, and insurance coverage rules.
- It calls for protecting indigenous and religious practices with entheogens and preventing commercial monopolies, while acknowledging unresolved tensions.
The US Congressional PATH Caucus now has a written record of what clinicians, researchers, veterans, tribal leaders, insurers, and regulators think about integrating psychedelics into healthcare. The PATH Caucus, co-chaired by Representatives Jack Bergman (R-MI) and Lou Correa (D-CA), presented a report on Thursday, October 1, analyzing responses to the public consultation opened in 2024.
Broad consensus, but with open issues
According to the caucus’s own memo, as reported by Marijuana Moment, the analysis finds a “broad consensus” that psychedelic-assisted therapy could offer a safe, equitable, and evidence-based treatment for a wide range of treatment-resistant conditions. The text, however, does not stop at enthusiasm: it speaks of “areas of agreement, tension, concern, and hope” that require further debate. Among the proposed policies is the requirement that benefits not depend on where a patient lives—whether in rural or urban areas—and that national data systems be established to monitor both benefits and unintended consequences.
The analysis of the responses was conducted by the consulting firm Pinney Associates. One of its researchers, Marion Coe, summarized the common thread with a direct statement: different federal agencies cannot continue to move in opposite directions regarding psychedelic research and regulation.
What the report recommends
The central proposal is coordination between federal agencies, states, and tribal governments. The report argues that such alignment is essential to reduce regulatory bottlenecks, ensure insurance coverage, set safety standards, and protect cultural knowledge, including the integration of indigenous customs into policy.
Concrete recommendations include developing federal guidelines for psychedelic therapy, creating multiple certification pathways for those administering it, and establishing a national system to track adverse events. It also highlights the need to define how these treatments will be covered by insurance, protect indigenous and religious entheogenic practices, and avoid over-commercialization and the monopolization of substances.
The clash between agencies
At the press conference, Correa attributed the momentum that has led his colleagues to take the matter seriously to the executive order signed this year by Donald Trump. He also pointed to a recent contradiction: the DEA is moving to further control psychedelics while the FDA works to accelerate therapeutic access. We have covered both developments: the DEA’s proposal regarding five psychedelic tryptamines and what was requested at the FDA public hearing.
Bergman, for his part, insisted that he is speaking of medical treatments administered by trained professionals in supervised clinical settings, not at home. This is the framework the caucus is working with: the healthcare model, with supervision as a prerequisite.
What it implies
A caucus report is not a law, nor does it bind any agency. It summarizes opinions and sets priorities, and its weight will depend on whether it translates into legislative bills or decisions by the FDA, the DEA, and the states. The interesting part lies in the absences and tensions: while the debate continues over who will certify therapists and how access will be ensured, autonomous use remains outside the framework—the caucus speaks only of treatments administered in clinical settings. That the text explicitly mentions the protection of indigenous and religious practices and the risk of monopoly is a sign that the debate no longer revolves solely around clinical trials. To follow the general context, you can consult our Psychedelics Guide.
Source
- Tom Angell / Marijuana Moment. Bipartisan Congressional Psychedelics Caucus Lays Out Plan For Federal And State Cooperation To Increase Therapeutic Access. Marijuana Moment, October 1, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
